Secondary malignant fibrous histiocytoma following refractory langerhans cell histiocytosis [0.03%]
难治性朗格汉斯细胞组织细胞增生症后恶性纤维组织细胞瘤的二次发病
Hirofumi Misaki,Takahiro Yamauchi,Hajime Arai et al.
Hirofumi Misaki et al.
We describe a rare case of secondary malignant fibrous histiocytoma (MFH) following Langerhans cell histiocytosis (LCH). A 23-year-old Japanese male exhibited systemic lymphadenopathy, multiple lung tumors, and osteolytic changes in bilater...
Immunohistochemical discrimination of plasmacytoid dendritic cells from myeloid dendritic cells in human pathological tissues [0.03%]
组织切片中浆细胞样树突状细胞和髓系树突状细胞的免疫组化鉴别诊断
Yuriko Nishikawa,Hiaki Sato,Takashi Oka et al.
Yuriko Nishikawa et al.
Until now, no method has been available to discriminate mature plasmacytoid DC (pDC) from myeloid DC (mDC) immunohistochemically. In this study, we report that these DC-subsets can be distinguished in routine pathological sections. Immature...
Histological variety of localized lymphoid hyperplasia of the large intestine: histopathological, immunohistochemical and genotypic findings of 16 cases [0.03%]
肠道局限性淋巴滤泡增生的组织学变异型：16例临床病理，免疫组化及遗传学分析
Masaru Kojima,Naoya Nakamura,Hideaki Itoh et al.
Masaru Kojima et al.
Previous reports emphasized that localized lymphoid hyperplasia (LLH) of the large intestine is usually histologically characterized by large lymphoid follicles with striking enlarged germinal centers, and a narrow surrounding mantle zone a...
Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP [0.03%]
利妥昔单抗-CHOPOCHOP治疗后非霍奇金B细胞淋巴瘤患者初次接触流感疫苗和再次接触流感疫苗的抗体应答减弱
Tohru Takata,Junji Suzumiya,Takahiko Ishikawa et al.
Tohru Takata et al.
To assess the humoral response to the influenza vaccine in patients undergoing R-CHOP therapy (rituximab combined with cyclophosphamide, doxorubicin, vincristine, and predonisolone) for non-Hodgkin lymphoma (NHL), the anti-hemagglutinin (HA...
Controlled Clinical Trial
Journal of clinical and experimental hematopathology : JCEH. 2009 May;49(1):9-13. DOI:10.3960/jslrt.49.9 2009
Oncogene associated cDNA microarray analysis shows PRAME gene expression is a marker for response to anthracycline containing chemotherapy in patients with diffuse large B-cell lymphoma [0.03%]
与吉西他滨联合顺铂化疗敏感相关的PRAME基因的表达研究及其作用机制探讨——Real-time PCR和Scrtatch细胞迁移实验联合应用
Riko Kawano,Kennosuke Karube,Masahiro Kikuchi et al.
Riko Kawano et al.
CHOP (cyclophosphamide, adriamycin, vincristine, and prednisolone) therapy achieves a response in more than 60% patients with diffuse large B-cell lymphomas (DLBCLs). However, DLBCL shows a heterogeneous response to chemotherapy, and some p...